Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Three immune checkpoint inhibitors—including a dual checkpoint blockade regimen, four BRAF or MEK targeted agents including combination regimens, and a viral therapy—have gained regulatory approval for malignant melanoma since 2011. Numerous label expansions for currently marketed therapies are expected to further shape the malignant melanoma market, and with emerging combination therapies demonstrating impressive results, the malignant melanoma market will become increasingly competitive as therapies vie for patient share and sales.
The malignant melanoma therapy market is set to experience rapid growth through 2025. What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market? What are the key unmet needs, and where do key drug development opportunities lie in this market?
Multiple agents notably PD-1 and BRAF/MEK inhibitors have secured regulatory approval for malignant melanoma in the United States, Europe, and Japan over 2014-2016. How have these novel therapies affected the use of existing therapies since their approval, and what will their impact be over the forecast period? What sales will the PD-1 inhibitors garner at the end of the forecast period? How will the use of immune checkpoint inhibitors change over the next ten years? How will use of these agents affect prescribing of other agents for malignant melanoma?
Two BRAF/MEK inhibitors combination regimens are approved for BRAF -mutation-positive unresectable or metastatic metastatic malignant melanoma. How are these combination therapies positioned in the malignant melanoma market, and what are the forecast expectations over the forecast period? What uptake can future BRAF/MEK combination therapies expect across different geographies?
The resectable (stage IIb-III) malignant melanoma population has few treatment options. What magnitude of uptake to we forecast for immune checkpoint inhibitors and BRAF/MEK inhibitors in the adjuvant setting? How will adjuvant therapies compete against one another? Which therapies hold the most promise in this setting?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 28 country-specific interviews with thought leaders. We also surveyed malignant melanoma specialists (including dermatologists) in each market on their treatment practices.
Epidemiology: Diagnosed incidence of malignant melanoma by stage of disease and resectability. Clinical and market-relevant drug-treatable populations.
Population segments in market forecast: Resectable (stage IIb-III), first-line unresectable or metastatic BRAF- wild-type, first-line unresectable or metastatic BRAF- mutation-positive, second-line unresectable or metastatic BRAF- wild-type, second-line unresectable or metastatic BRAF- mutation-positive, third-line unresectable or metastatic BRAF- wild-type, third- and fourth-line unresectable or metastatic BRAF- mutation-positive.
Emerging therapies: Phase II: 32 drugs; Phase III: 6 drugs. Coverage of 28 select Phase I products.